转债代码：113633 转债简称：科沃转债 科沃斯机器人股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 届董事会第二次会议在公司会议室召开。本次会议的会议通知已于 2025 年 6 月 董事 9 名，实到董事 9 名（其中：以通讯表决方式出席会议 4 名），符合召开董 事会会议的法定人数。会议由公司董事长钱东奇先生主持，公司高级管理人员列 席了会议。会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，表决形成的决议合法、有效。会议审议并通过了如下议 案: 证券代码：603486 证券简称：科沃斯 公告编号：2025-048 君合律师事务所上海分所出具了《关于科沃斯机器人股份有限公司 2024 年 股票期权与限制性股票激励计划调整及预留授予事项的法律意见书》。 上海荣正企业咨询服务（集团）股份有限公司出具了《关于科沃斯机器人股 份有限公司 2024 年股票期权与限制性股票激励计划调整及预留授予相关事项之 独立财务顾问报告》。 表决结果：同意 8 票、反对 0 ...

中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 君合律师事务所上海分所 关于科沃斯机器人股份有限公司 法律意见书 科沃斯机器人股份有限公司： 《证券法》 君合律师事务所上海分所（以下简称"本所"）为具有从事法律业务资格的 律师事务所分所。本所接受科沃斯机器人股份有限公司（以下简称"公司"或 "科沃斯"）的委托，委派本所律师以特聘法律顾问的身份，就公司 2024 年股 票期权与限制性股票激励计划预留部分授予（以下简称"本次激励计划预留授 予"）相关事宜出具本法律意见书。 本法律意见书系根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、中国证券监督管理委员 会（以下简称"中国证监会"）颁布的《上市公司股权激励管理办法》（以下简 称"《管理办法》"）等在本法律意见书出具日以前中国（仅为出具本法律意见 书之目的，不包括香港特别行政区、澳门特别行政区和台湾地区）正式公布并实 施的法律、法规及规范性文件和《 ...

证券代码：600039 证券简称：四川路桥 公告编号：2025-066 四川路桥建设集团股份有限公司 第八届监事会第四十四次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）本次监事会会议的召开符合《公司法》、公司《章程》的规定。 （二）本次监事会于 2025 年 6 月 27 日在公司以现场结合通讯方式召开，会 议通知于 2025 年 6 月 20 日以书面、电话的方式发出。 （四）本次监事会由监事会主席黄卫主持，公司部分高级管理人员列席了会 议。 （三）本次监事会应出席人数 6 人，实际出席人数 6 人。其中监事谭德彬、 赵帅、刘胜军、李亚舟以通讯方式参会。 二、监事会会议审议情况 （一）审议通过了《关于重组标的资产业绩承诺期满减值测试情况的议案》 根据公司与蜀道投资集团有限责任公司、四川高速公路建设开发集团有限公 司、四川藏区高速公路有限责任公司和四川高路文化旅游发展有限责任公司（以 下统称业绩补偿义务人）签署的《业绩补偿协议》等相关协议，公司委托四川天 健华衡资产评估有限公司 ...

根据《2021 年限制性股票激励计划（草案）》（以下简称"《激励计划》"） 《2021 年限制性股票激励计划实施考核管理办法》及《2021 年限制性股票激励 计划管理办法》的相关规定，公司本次激励计划首次授予部分第三个解除限售期 解除限售条件已经成就，解除限售的激励对象主体资格合法、有效，可以按照相 关规定解除限售。本次激励计划对各激励对象解除限售安排未违反有关法律、法 规的规定，不存在损害公司及全体股东利益的情形。同意公司对本次激励计划首 次授予部分 519 名激励对象第三个解除限售期的 3798.075 万股限制性股票按照 相关规定解除限售。 详见当日《中国证券报》《上海证券报》《证券时报》《证券日报》及上 海证券交易所网站（http://www.sse.com.cn）刊登的"物产中大关于 2021 年限 制性股票激励计划首次授予部分第三个解除限售期解除限售条件成就的公告"。 特此公告。 证券代码：600704 证券简称：物产中大 编号：2025-042 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 物产中大集团股 ...

证券代码：300708 证券简称：聚灿光电 公告编号：2025-046 聚灿光电科技股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 聚灿光电科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 6 月 于 <聚灿光电科技股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案="草 案"> 及其摘要 的议案》等相关议案，具体内容详见公司于 2025 年 6 月 17 日收盘后在巨潮资讯 网(http://www.cninfo.com.cn)刊登的相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《深圳证 券交易所创业板上市公司自律监管指南第 1 号——业务办理》（以下简称"《自 律监管指南》"）等法律、法规及规范性文件的要求，遵循上市公司《信息披露 管理制度》 公司针对 2025 年限制性股票激励计划（以下简称"激励计划"）采取了充分必要 的保密措施，同时对激励计划的内幕信息知情人做了必要登记，并对内 ...

Core Points - The company announced the first vesting results of the 2024 restricted stock incentive plan, with a total of 418,656 shares vested [1][10] - The shares for this vesting were sourced from the company's repurchase of its A-share common stock from the secondary market [9] Summary of Relevant Sections Decision-Making Process and Disclosure - On April 28, 2024, the company's board and supervisory board approved the draft of the 2024 restricted stock incentive plan and related proposals [2][3] - The plan was publicly disclosed on April 29, 2024, on the Shanghai Stock Exchange website [2] Vesting Details - The total number of shares granted was 1,046,640, with 418,656 shares vested, representing 40% of the granted shares [7] - The vesting included 180 individuals, with core technical personnel and other key employees being the main recipients [9] Stock Source and Structure Changes - The vested shares were sourced from the company's repurchased A-share common stock, meaning there was no change in the total share capital of the company [9] - The controlling shareholder's stake remained unchanged before and after the vesting [9] Verification and Registration - The company received a verification report from an accounting firm confirming the subscription funds for the vested shares, totaling approximately RMB 9.54 million [9][10] - The registration of the vested shares was completed on June 26, 2025, as confirmed by the China Securities Depository and Clearing Corporation [10]

Core Viewpoint - The company anticipates gradual improvement in performance in Q2 2025 and the second half of the year, following the end of inventory destocking by downstream customers in the home respiratory device component sector [3]. Group 1: Home Respiratory Devices and Cochlear Implants - The company's core business involves the development, manufacturing, and sales of home respiratory devices and cochlear implant components [3]. - In 2024, the company expects a return to normal growth rates for home respiratory device component orders, supported by the Malaysian base potentially avoiding tariff risks, which is expected to drive long-term revenue growth [3]. - Revenue from cochlear implant components is showing steady growth, and new product component revenues are rapidly increasing, indicating effective diversification in business segments [3]. - Due to the impact of the Spring Festival on Q1 2025, revenue growth has slowed compared to the full year of 2024, but performance is expected to improve gradually as order deliveries resume [3]. Group 2: Blood Glucose Management and Production Expansion - The company has made breakthroughs in core technologies such as precision molds and liquid silicone, focusing on products like disposable injection pens, continuous glucose monitoring (CGM) devices, and insulin patch pumps [4]. - Collaborations with global medical device leaders are ongoing in the fields of blood glucose management, IVD diagnostics, and cardiovascular devices [4]. - A fully automated production project for insulin injection pens developed for international clients has achieved large-scale production in 2024 [4]. - The company has completed the core R&D work for its self-designed "Beautiful Pen," which includes three major technology directions [4]. - The Malaysian production base has successfully completed the first two phases of capacity construction, with the third phase expected to be operational by the end of 2025 [4]. Group 3: Stock Incentive Plan - The company has announced a stock incentive plan for 2025, granting a total of 5 million shares to no more than 304 core employees, representing 1.23% of the total share capital [5]. - The performance assessment for the stock incentive plan is based on revenue or net profit for 2023, with target growth rates for 2025-2027 set at no less than 56.25%, 95.31%, and 144.14% respectively [5]. - The triggering growth rates for 2025-2027 are set at no less than 44.00%, 72.80%, and 107.36% respectively, reflecting the company's confidence in long-term growth [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 经审议，监事会认为：鉴于公司2024年半年度以及2024年年度利润分配方案已实施完毕，公司董事会根 据2022年年度股东大会授权对2023年限制性股票激励计划的相关事项进行调整，审议程序合法合规，符 合《上市公司股权激励管理办法》等有关法律、法规、规范性文件和公司《2023年限制性股票激励计划 （草案）》的相关规定，不存在损害公司及全体股东利益的情形。因此，监事会同意本议案。 表决结果：同意3票，反对0票，弃权0票。 证券代码：688076 证券简称：诺泰生物 公告编号：2025-051 江苏诺泰澳赛诺生物制药股份有限公司 第四届监事会第二次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）第四届监事会第二次会议于2025年6月26日 下午16:00以通讯会议方式召开，会议通知于2025年6月20日以电子邮件方式送达全体监事。本次会议应 出席监事3人，实际出席监事3人，会议由监事会主席殷新波先生主持。会议的召开 ...

Core Viewpoint - The company has announced the achievement of vesting conditions for the second category of restricted stock under its 2022 incentive plan, allowing for the vesting of 973,000 shares at an adjusted grant price of 25.24 yuan per share [1][17]. Summary by Sections 1. Overview of the 2022 Restricted Stock Incentive Plan - The company held a shareholder meeting on October 17, 2023, approving the incentive plan which includes two categories of restricted stock [2]. - The grant price for the second category of restricted stock is set at 26.61 yuan per share, with adjustments possible due to corporate actions [2][3]. 2. Vesting Arrangements - The vesting schedule for the first grant of the second category of restricted stock includes three vesting periods: 30% after 12 months, 40% after 24 months, and 30% after 36 months from the grant date [3][4]. - For the reserved grants, the vesting conditions are similar, with adjustments based on the timing of the grant [4]. 3. Performance Assessment Criteria - The performance assessment for vesting includes annual targets for revenue growth and net profit growth from 2022 to 2024 [5][20]. - Specific targets include a revenue growth rate of 10% for 2022, 20% for 2023, and 20% for 2024, with corresponding net profit growth rates [5][20]. 4. Approval Process - The company has followed a structured approval process, including board meetings and shareholder approvals, to implement the incentive plan [6][8][9]. - Legal opinions and independent assessments were obtained to ensure compliance with regulations [7][8]. 5. Current Vesting Status - As of the latest board meeting, 201 eligible participants have met the vesting conditions, with a total of 1,035,300 shares available for vesting [17][27]. - The breakdown includes 978,300 shares for the first grant and 57,000 shares for reserved grants [17][26]. 6. Financial Impact - The company will account for the fair value of the vested shares in accordance with accounting standards, impacting its financial statements [28].

Core Viewpoint - The report serves as an independent financial advisory opinion on the 2025 Restricted Stock Incentive Plan of Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd, ensuring compliance with relevant laws and regulations while assessing the plan's feasibility and potential impact on the company's sustainable development and shareholder interests [1][2][3]. Summary by Sections Section 1: Introduction - The independent financial advisor, Shanghai Xinguang Yihe Enterprise Management Consulting Co., Ltd, has been commissioned to provide an advisory report on the 2025 Restricted Stock Incentive Plan for Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd [1]. Section 2: Assumptions - The report is based on several assumptions, including the stability of current laws and regulations, the accuracy of information provided by the company, and the absence of unforeseen adverse factors [2][5]. Section 4: Main Content of the Incentive Plan - The incentive plan involves granting second-class restricted stocks sourced from either newly issued A-shares or repurchased A-shares from the secondary market [6][7]. - A total of 1.073375 million restricted stocks will be granted, representing approximately 1.22% of the company's total share capital of 88.048706 million shares [6][7]. - The plan's effective period is set for a maximum of 60 months, with specific vesting arrangements and a purchase price of 48.88 yuan per share [11][8]. Section 5: Independent Financial Advisor's Opinion - The advisor confirms that the incentive plan complies with relevant regulations and does not pose any significant risk to the company or its shareholders [19][20]. - The plan is deemed feasible in terms of operational procedures and aligns with the company's strategic goals [21]. Section 6: Financial Impact - The implementation of the incentive plan is expected to positively influence the company's sustainable operations and shareholder equity by motivating key personnel [25]. - The advisor emphasizes that the funding for the incentive plan will come from the participants' own resources, ensuring no financial assistance from the company [26]. Section 7: Performance Assessment - The performance assessment framework includes both company-wide and individual performance metrics, focusing on revenue and gross profit targets for the years 2025 to 2028 [15][18]. - The plan aims to align the interests of the company, shareholders, and key personnel, fostering a culture of accountability and performance [27].